Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Infection and Chemotherapy
Published in: Journal of Infection and Chemotherapy 3/2013

01-06-2013 | Original Article

Minimal biofilm eradication concentration of antimicrobial agents against nontypeable Haemophilus influenzae isolated from middle ear fluids of intractable acute otitis media

Authors: Shin Takei, Muneki Hotomi, Noboru Yamanaka

Published in: Journal of Infection and Chemotherapy | Issue 3/2013

Login to get access

Abstract

Nontypeable Haemophilus influenzae (NTHi) makes the clinical course of acute otitis media (AOM) intractable by forming a biofilm that may hamper the clearance of the bacteria from middle ear cavity. In this study, we evaluated the minimum biofilm eradication concentration (MBEC) of antimicrobial agents against biofilm-forming NTHi strains. Twelve NTHi strains isolated from middle ear fluids of Japanese children with intractable AOM before antimicrobial treatment were evaluated for MBEC of fluoroquinolones in comparison with those of β-lactams and macrolides. AMPC and CDTR required much higher concentration, i.e., high MBECs, to suppress the biofilm formation of NTHi. In contrast, fluoroquinolones followed by macrolides showed lower MBECs. MBEC would be a good parameter to infer the efficacies of antimicrobials against NTHi in biofilm.
Literature
1.
Teele DW, Klein JO, Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis. 1989;160:83–94.PubMedCrossRef
2.
Monasta L, Ronfani L, Marchetti F, Montico M, Vecchi Brumatti L, Bavcar A, et al. Burden of disease caused by otitis media: systematic review and global estimates. PLoS ONE. 2012;7:e36226.PubMedCrossRef
3.
Hotomi M, Yamanaka N, Shimada J, Ikeda Y, Faden H. Factors associated with clinical outcomes in acute otitis media. Ann Otol Rhinol Laryngol. 2004;113:846–52.PubMed
4.
Murphy TF, Faden H, Bakaletz LO, Kyd JM, Forsgren A, Campos J, et al. Nontypeable Haemophilus influenzae as a pathogen in children. Pediatr Infect Dis J. 2009;28:43–8.PubMedCrossRef
5.
Hotomi M, Fujihara K, Billal DS, Suzuki K, Nishimura T, Baba S, et al. Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. Antimicrob Agents Chemother. 2007;51:3969–76.PubMedCrossRef
6.
Moxon ER, Sweetman WA, Deadman ME, Ferguson DJ, Hood DW. Haemophilus influenzae biofilms: hypothesis or fact? Trends Microbiol. 2008;16:95–100.PubMedCrossRef
7.
8.
Bakaletz LO. Bacterial biofilms in otitis media: evidence and relevance. Pediatr Infect Dis J. 2007;26:S17–9.PubMedCrossRef
9.
Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318–22.PubMedCrossRef
10.
11.
Anderson GG, O’Toole GA. Innate and induced resistance mechanisms of bacterial biofilms. Curr Top Microbiol Immunol. 2008;322:85–105.PubMedCrossRef
12.
American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media. Diagnosis and management of acute otitis media. Pediatrics. 2004;113:1451–5.CrossRef
13.
Grubb MS, Spaugh DC. Treatment failure, recurrence, and antibiotic prescription rates for different acute otitis media treatment methods. Clin Pediatr (Phila). 2010;49:970–5.CrossRef
14.
Moriyama S, Hotomi M, Shimada J, Billal DS, Fujihara K, Yamanaka N. Formation of biofilm by Haemophilus influenzae isolated from pediatric intractable otitis media. Auris Nasus Larynx. 2009;36:525–31.PubMedCrossRef
15.
Subcommittee of Clinical Practice Guideline for Diagnosis and Management of Acute Otitis Media in Children (Japan Otological Society, Japan Society for Pediatric Otorhinolaryngology, Japan Society for Infectious Diseases in Otolaryngology). Clinical practice guidelines for the diagnosis and management of acute otitis media (AOM) in children in Japan. Auris Nasus Larynx 2012;39:1–8.
16.
Murphy TF, Brauer AL, Sethi S, Kilian M, Cai X, Lesse AL. Haemophilus haemolyticus: a human respiratory tract commensal to be distinguished from Haemophilus influenzae. J Infect Dis. 2007;195:81–9.PubMedCrossRef
17.
Kaji C, Watanabe K, Apicella MA, Watanabe H. Antimicrobial effect of fluoroquinolones for the eradication of nontypeable Haemophilus influenzae isolates within biofilms. Tohoku J Exp Med. 2008;214:121–8.PubMedCrossRef
18.
National Committee for Clinical Laboratory Standards (2004) Performance standards for antimicrobial susceptibility testing. Fourteenth informational supplement. Approved standard M100-S14. Wayne, PA: NCCLS.
19.
Billal DS, Fedorko DP, Yan SS, Hotomi M, Fujihara K, Nelson N, et al. In vitro induction and selection of fluoroquinolone-resistant mutants of Streptococcus pyogenes strains with multiple emm types. J Antimicrob Chemother. 2007;59:28–34.PubMedCrossRef
20.
Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol. 1999;37:1771–6.PubMed
21.
Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1–10.PubMedCrossRef
22.
Anderl JN, Franklin MJ, Stewart PS. Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Chemother. 2000;44:1818–24.PubMedCrossRef
23.
Fux CA, Costerton JW, Stewart PS, Stoodley P. Survival strategies of infectious biofilms. Trends Microbiol. 2005;13:34–40.PubMedCrossRef
24.
Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15:167–93.PubMedCrossRef
25.
Yamanaka N, Sugita R, Uno Y, Matsubara S, Hayashi Y, Sawada S. Clinical efficacy of tosufloxacin tosilate hydrate for the treatment of acute otitis media in children (in Japanese). Practica Oto-Rhino-Laryngologica 2012;105:381–392
26.
Dagan R, Arguedas A, Schaad UB. Potential role of fluoroquinolone therapy in childhood otitis media. Pediatr Infect Dis J. 2004;23:390–8.PubMedCrossRef
27.
Reid G, Sharma S, Advikolanu K, Tieszer C, Martin RA, Bruce AW. Effects of ciprofloxacin, norfloxacin, and ofloxacin on in vitro adhesion and survival of Pseudomonas aeruginosa AK1 on urinary catheters. Antimicrob Agents Chemother. 1994;38:1490–5.PubMedCrossRef
Metadata
Title
Minimal biofilm eradication concentration of antimicrobial agents against nontypeable Haemophilus influenzae isolated from middle ear fluids of intractable acute otitis media
Authors
Shin Takei
Muneki Hotomi
Noboru Yamanaka
Publication date
01-06-2013
Publisher
Springer Japan
Published in
Journal of Infection and Chemotherapy / Issue 3/2013
Print ISSN: 1341-321X
Electronic ISSN: 1437-7780
DOI
https://doi.org/10.1007/s10156-013-0592-y

Other articles of this Issue 3/2013

Journal of Infection and Chemotherapy 3/2013 Go to the issue

Guideline

Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring

Original Article

Nationwide survey of the development of drug-resistant pathogens in the pediatric field in 2007 and 2010: drug sensitivity of Streptococcus pneumoniae in Japan (second report)

Review Article

Pneumococcal vaccine and opsonic pneumococcal antibody

Case Report

Multiple liver cyst infection caused by Salmonella ajiobo in autosomal dominant polycystic kidney disease

Note

Is paromomycin the drug of choice for eradication of Blastocystis in adults?

Original Article

Mumps Hoshino and Torii vaccine strains were distinguished from circulating wild strains
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits